J Korean Med Sci.  2005 Apr;20(2):340-343. 10.3346/jkms.2005.20.2.340.

Analysis of Loss of Heterozygosity in Korean Patients with Keratoacanthoma

• Ha TW
• Han KH
• Son DG
• Kim SP
• Kim DK

• KMID: 1095217
• DOI: http://doi.org/10.3346/jkms.2005.20.2.340

Abstract

Loss of heterozygosity (LOH) has been established as an important genetic mechanism giving rise to malignant neoplasia. The mechanism of LOH has been shown to cause basal cell carcinoma and malignant melanoma as well as other types of skin cancer. A few studies on LOH in sporadic keratoacanthomas have been reported. The purpose of this study was to investigate the significance of LOH in the pathogenesis of sporadic keratoacanthomas developed in 10 Korean patients. The presents of LOH at 7 microsatellite markers (D2S286, D3S1317, D5S346, D9S160, D9S171, D10S185, and D17S261) were evaluated in sporadic keratoacanthomas. LOH was found in only 1 of 10 cases at D10S185. The low frequency of LOH detected in this study suggests that LOH may not be significant in the induction of sporadic keratoacanthomas.

Keyword

Loss of Heterozygosity; Keratoacanthoma

MeSH Terms

Adult
Aged
Female
Humans
Keratoacanthoma/*genetics
*Loss of Heterozygosity
Male
Middle Aged
Research Support, Non-U.S. Gov't

Figure

• 

  Fig. 1 LOH at chromosome region 10q (D10S185) in patient No. 10. The arrow indicates the reduction of signal intensity in tumor (T) DNA as compared with corresponding normal (N) DNA.

Reference

1. Kern WH, McCray MK. The histopathologic differentiation of keratoacanthoma and squamous cell carcinoma of the skin. J Cutan Pathol. 1980. 7:318–325.

2. Schwartz RA. Keratoacanthoma. J Am Acad Dermatol. 1994. 30:1–19.

3. Sanders GH, Miller TA. Are kearatoacanthomas really squamous cell carcinomas? Ann Plast Surg. 1982. 9:306–309.

4. Requena L, Romero E, Sanchez M, Ambrojo P, Sanchez Yus E. Aggressive keratoacanthoma of the eyelid: "malignant" keratoacanthoma or squamous cell carcinoma? J Dermatol Surg Oncol. 1990. 16:564–568.

5. Hodak E, Jones RE, Ackerman AB. Solitary keratoacanthoma is a squamous cell carcinoma: three examples with metastases. Am J Dermatopathol. 1993. 15:332–342.

6. Fearon ER. Human cancer syndromes: clues to the origin nature of cancer. Science. 1997. 278:1043–1050.

7. Mao LI, Fan YH, Lotan R, Hong WK. Frequent abnormalities of FHIT, a candidate tumor suppressor gene, in head and neck cancer cell lines. Cancer Res. 1996. 56:5128–5131.

8. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990. 61:759–767.

9. Califano J, van der Riet P, Westra W, Nawroz H, Clayman G, Piantadosi S, Corio R, Lee D, Greenberg B, Koch W, Sidransky D. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res. 1996. 56:2488–2492.

10. Peris K, Magrini F, Keller G, Manente L, D'Alessandro E, Onorati MT, Hofler H, Chimenti S. Analysis of microsatellite instability and loss of heterozygosity in keratoacanthoma. Arch Dermatol Res. 1997. 289:185–188.

11. Langenbach N, Kroiss MM, Rüschoff J, Schlegel J, Landthaler M, Stolz W. Assessment of microsatellite instability and loss of heterozygosity in sporadic keratoacanthomas. Arch Dermatol Res. 1999. 291:1–5.

12. Waring AJ, Takata M, Rehman I, Rees JL. Loss of heterozygosity analysis of keratoacanthoma reveals multiple differences from cutaneous squamous cell carcinoma. Br J Cancer. 1996. 73:649–653.

13. Kim DK, Kim JY, Kim HT, Han KH, Shon DG. A specific chromosome aberration in a keratoacanthoma. Cancer Genet Cytogenet. 2003. 142:70–72.

14. Akalu A, Reichardt JK. A reliable PCR amplification method for microdissected tumor cells obtained from paraffin-embedded tissue. Genet Anal. 1999. 15:229–233.

15. Sepp T, Yates JR, Green AJ. Loss of heterozygosity in tuberous sclerosis hamartomas. J Med Genet. 1996. 33:962–964.

16. Matt D, Xin H, Vortmeyer AO, Zhuang Z, Burg G, Böni R. Sporadic trichoepithelioma demonstrates deletions at 9q22.3. Arch Dermatol. 2000. 136:657–660.

17. Verhoef S, Schrander-Stumpel CT, Vuzevski VD, Tempelaars A, Jansen LA, Malfeyt GA, Ceelen TL, Lindhout D, Halley DJ, van den Ouweland AM. Familial cylindromatosis mimicking tuberous sclerosis complex and confirmation of the cylindromatosis locus, CYLD1, in a large family. J Med Genet. 1998. 35:841–845.

18. Böni R, Zhuang Z, Albuquerque A, Vortmeyer A, Duray P. Loss of heterozygosity detected on 1p and 9q in microdissected atypical nevi. Arch Dermatol. 1998. 134:882–883.

19. Pack S, Turner ML, Zhuang Z, Vortmeyer AO, Böni R, Skarulis M, Marx SJ, Darling TN. Cutaneous tumors in patients with multiple endocrine neoplasia type 1 show allelic deletion of the MEN1 gene. J Invest Dermatol. 1998. 110:438–440.

20. Colman SD, Williams CA, Wallace MR. Benign neurofibromas in type1 neurofibromatosis (NF1) show somatic deletions of the NF1 gene. Nat Genet. 1995. 11:90–92.

21. Mertens F, Heim S, Mandahl N, Johansson B, Rydholm A, Biorklund A, Wennerberg J, Jonsson N, Mitelman F. Clonal chromosome aberrations in a keratoacanthoma and a basal cell papilloma. Cancer Genet Cytogenet. 1989. 39:227–232.

22. Schwartz RA, Torre DP. The Muir-Torre syndrome: a 25-year retrospect. J Am Acad Dermatol. 1995. 33:90–104.

23. Rehman I, Quinn AG, Healy E, Rees JL. High frequency of loss of heterozygosity in actinic keratoses, a usually benign disease. Lancet. 1994. 344:788–789.

24. Borkowski A, Bennett WP, Jones RT, Borkowski P, Harris CC, Ferreira LR, Kao GF, Trump BF. Quantitative image analysis of p53 protein accumulation in keratoacanthomas. Am J Dermatopathol. 1995. 17:335–338.

25. Perez MI, Robins P, Biria S, Roco J, Siegel E, Pellicer A. P53 oncoprotein expression and gene mutations in some keratoacanthomas. Arch Dermatol. 1997. 133:189–193.

26. Clausen OP, Beigi M, Bolund L, Kølvraa S, Gjersvik PJ, Mork G, de Angelis PM. Keratoacanthomas frequently show chromosomal aberrations as assessed by comparative genomic hybridization. J Invest Dermatol. 2002. 119:1367–1372.